Abstract：Objective To study the clinical significance of serum superoxide dismutase (SOD), brain-derived nutrition factor (BDNF) and scores of positive and negative symptom scale (PANSS) scale in patients with chronic schizophrenia, and to provide guidance for patients′ condition and prognosis evaluation. Methods From March 2018 to March 2020, 80 patients with chronic schizophrenia admitted to the Department of Psychiatric of the Fourth People′s Hospital of Wuhu City, Anhui (hereinafter referred to as “our hospital”) were selected as the observation group, and 80 healthy normal people served who received physical examination in our hospital during the same period were selected as the control group. Enzyme-linked immunosorbent assay was used to detect serum SOD and BDNF levels in the two groups, and PANSS score was used to assess psychopathological symptoms. The correlation between serum SOD and BDNF levels and PANSS score were analyzed. Results The serum SOD level of the observation group was higher than that of the control group, while BDNF level was lower than that in the control group, and the differences were statistically significant (P < 0.05). The general pathology, negative symptoms, positive symptoms scores and total scores of the observation group were higher than those of the control group, and the differences were statistically significant (P < 0.05). Serum SOD level was positively correlated with negative symptoms, positive symptom scores and total scores (r ＞ 0, P ＜ 0.05); serum BDNF level was positively correlated with general pathological scores (r ＞ 0, P ＜ 0.05), while negatively correlated with PANSS negative symptoms and positive symptoms (r ＜ 0, P ＜ 0.05). Conclusion The serum SOD level and PANSS score of patients with chronic schizophrenia are significantly increased, and the BDNF level is significantly decreased, which is related to the severity of the disease. The detection of the above indicators helps to judge the condition and assess the prognosis.
朱明 宋传福. 慢性精神分裂症患者血清SOD、BDNF、PANSS量表评分及临床意义[J]. 中国医药导报, 2020, 17(23): 118-121.
ZHU Ming SONG Chuanfu. Clinical significance of serum SOD, BDNF and scores of PANSS scale in patients with chronic schizophrenia. 中国医药导报, 2020, 17(23): 118-121.
[1] Fillman SG，Weickert TW，Lenroot RK，et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca′s area volume [J]. Mol Psychiatry，2016，21（8）：1090-1098.
[2] Kinoshita T，Bai YM，Kim JH，et al. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia：a multicentre，randomized，double-blind，6-week，placebo-controlled study [J]. Psychopharmacology （Berl），2016，233：2663-2674.
[3] 戴新国，叶飞，吴慧，等.慢性精神分裂症血清同型半胱氨酸与认知功能的关系[J].中国临床心理学杂志，2015， 23（5）：865-866，864.
[4] 王晓燕，王伟灵，丁彬彬，等.慢性精神分裂症患者血清Hcy、血脂水平与认知障碍的关系[J].检验医学，2015，30（12）：1198-1202.
[5] 吴宇杰，李君，陈舒弋，等.精神分裂症患者非酶类抗氧化分子水平的研究[J].中国医药导报，2015，12（28）：51-53，62.
[6] 李淑香，范宏振，丁琳，等.不同抗精神病药物对精神分裂症患者血清催乳素水平的影响[J].中国医药导报，2015， 12（18）：119-121.
[7] 周蓉，孙剑，汪卫华，等.精神分裂症患者血清脑源性神经营养因子、胶质源性神经营养因子水平变化[J].山东医药，2018，58（11）：58-60.
[8] 肖文焕，陈宽玉，唐小伟，等.首发精神分裂症患者治疗前后血清BDNF和GDNF水平的变化[J].皖南医学院学报，2016，35（5）：464-466.
[9] 许俊亭.DSM-Ⅳ临床定式访谈（SCID）的信度、效度研究进展[J].四川精神卫生，2014，27（3）：285-287.
[10] 马婉.精神症状评定量表的信效度再检验及临床应用优势[D].杭州：浙江大学，2015.
[11] Karrer T，Bassett DS，Derntl B，et al. Brain-based ranking of cognitive domains to predict schizophrenia [J]. Hum Brain Mapp，2019，40（15）：4487-4507.
[12] 晁阳阳，盛卫勇，赵瑾，等.首发精神分裂症外周血氧化应激状态改变[J].中国神经精神疾病杂志，2016，42（8）：449-453.
[13] 翟媛媛，张辉，马瑾，等.精神分裂症患者甲状腺激素变化特征及其与白蛋白的相关性[J].中国医药导报，2019， 16（36）：73-76.
[14] 李丹，徐阿红，易正辉，等.氧化应激与血脂代谢在精神分裂症中的关联分析[J].检验医学，2017，32（9）：749-752.
[15] 姚传斌，胡乃启，王志广，等.外周血氧化应激因子、IL-6、S100-β、NT-3与精神分裂症症状的相关性研究[J].国际精神病学杂志，2018，45（2）：237-239，249.
[16] Sanada K，Zorrilla I，Iwata Y，et al. The Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia：A Systematic Review and Meta-Analysis [J]. Int J Mol Sci，2016，17（10）：1766.
[17] 牛莉莉，温科奇，熊鹏，等.首发精神分裂症治疗前后血清NGF、BDNF、GFAP与临床症状的相关性研究[J].精神医学杂志，2015，28（1）：10-12.
[18] 万静，黄彩英，平军娇，等.首发精神分裂症NGF、Hcy血清浓度与临床症状相关性研究[J].中国医学创新，2018， 15（21）：41-44.
[19] 桂燕，邢葆平，黄婉立，等.低频重复经颅磁刺激治疗精神分裂症患者的效果及对患者血清BDNF水平的影响[J].中国现代医生，2019，57（12）：1-3，8.
[20] 张欣，孟杰，吕华，等.首发精神分裂症患者血清miR-103 a和BDNF的表达及临床意义[J].山西医科大学学报，2019，50（8）：1174-1178.
[21] 段维维，唐小伟，杨韦，等.男性慢性精神分裂症患者血清脑源性神经营养因子和胶质源性神经营养因子水平及认知功能的对照研究[J].临床精神医学杂志，2016， 26（5）：329-331.
[22] 费小聪，陈海支，杨胜良，等.脑源性神经生长因子对首发精神分裂症患者早期改善的预测作用[J].浙江医学，2016，38（18）：1491-1493，1497.
[23] Tomasz P，Marta GG，El■bieta T，et al. An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia：secondary outcome analysis of the OFFER randomized clinical trial [J]. Psychopharmacology（Berl），2019，236（9）：2811-2822.
[24] Fountoulakis K，Dragioti E，Theofilidis T，et al. Staging of Schizophrenia With the Use of PANSS：An International Multi-Center Study [J]. Int J Neuropsychopharmacol，2019，22（11）：681-697.
[25] 辛一帆，李光梅，郑兴华.精神分裂症患者社会支持程度与血清神经功能指标水平及阴性症状、抑郁症状的相关性[J].神经疾病与精神卫生，2019，19（4）：371-376.
[26] 温科奇，牛莉莉，熊鹏，等.血清蛋白因子对精神分裂症首次发病患者的疗效预测[J].临床精神医学杂志，2015， 25（6）：365-368.
[27] 杨明杰.精神分裂症患者血清蛋白因子水平的表达特点及其意义[J].解放军预防医学杂志，2018，36（9）：1207-1210.
2020, Vol. 17 
京公网安备 11010502046598号